Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

CAPLIPOINT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+10.5%Reaction day

₹1831.00

prior close

₹1828.90

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.0%+10.5% vs market

Pharmaceuticals peers, median of 161sector+0.4%+10.2% vs sector

On the reaction day the stock moved 10.5 pts more than Nifty Smallcap 250 and 10.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

-0.2

15m

-0.4

30m

+6.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+10.5+0.0+10.5+0.4+10.2

Next day

+9.7-0.4+10.1+0.0+9.6

+8.5-1.8+10.4-0.4+9.0

+11.4-0.7+12.1+0.0+11.4

+10.1-0.6+10.7+1.2+9.0

+10.7+0.1+10.6+2.0+8.7

+13.7+1.1+12.6+1.0+12.7

15d

+11.2+1.6+9.6+1.4+9.8

+29.7+3.0+26.6+2.2+27.4

+45.2+7.1+38.1+7.9+37.3

+35.9+8.9+27.0+8.1+27.8

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Caplin Point Laboratories reported strong full-year FY26 results with consolidated revenue from operations of ₹2,187 Crores, up 12.9% YoY from ₹1,937 Crores. Net profit after tax (PAT) grew 20.1% to ₹650 Crores versus ₹541 Crores in the prior year. The company declared an interim dividend of ₹4 per share (200% on face value ₹2). US market revenue stood at ₹471 Crores, delivering 28.7% YoY growth. EBITDA margin showed expansion to approximately 36.7% from 34.9% in FY25. The auditor, Brahmayya & Co, issued an unmodified (clean) opinion on both standalone and consolidated financial statements with no going concern issues. Free cash reserves stood at ₹1,471 Crores with liquid assets of ₹2,726 Crores.

Likely market impact

Strong financial performance with 20% PAT growth and margin expansion signals operational efficiency improvements. The clean audit opinion and robust cash position are positive indicators for shareholders.